Pentixapharm Holding AG Stock
Price
Target price
€2.44
€2.44
2.490%
0.06
2.490%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pentixapharm Holding AG Stock
There is an upward development for Pentixapharm Holding AG compared to yesterday, with an increase of €0.060 (2.490%).
Pros and Cons of Pentixapharm Holding AG in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
![EQS-News: [68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market](https://www.sharewise.com/assets/news/news2-43a650f8b830e72801e4feae71d912bbee126d79fc8a8386e39fa6ba5787dbcb.png)
EQS-News: [68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
EQS-News: [68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
EQS-News: Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
EQS-News: Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review
EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review